NCT00874978View on ClinicalTrials.gov

The Efficacy and Safety of Lenalidomide Monotherapy in Red Blood Cell Transfusion Dependent Subjects With Myelodysplastic Syndrome (MDS) Associated With Del (5q) Abnormality

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

May 31, 2016

Study Completion Date

May 31, 2016

Conditions
Myelodysplastic Syndromes
Interventions
DRUG

lenalidomide

Oral lenalidomide 10mg (two 5mg capsules) daily on days 1-21 every 28 days for up to 6 cycles.

Trial Locations (1)

SE5 9RS

King's College Hospital NHS Foundation Trust, London

All Listed Sponsors
lead

King's College Hospital NHS Trust

OTHER

NCT00874978 - The Efficacy and Safety of Lenalidomide Monotherapy in Red Blood Cell Transfusion Dependent Subjects With Myelodysplastic Syndrome (MDS) Associated With Del (5q) Abnormality | Biotech Hunter | Biotech Hunter